Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases including Alzheimer's and Parkinson's.

Muna Therapeutics

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 and based in Copenhagen, Denmark. 

Muna discovers and develops therapies that slow or stop devastating neurodegenerative diseases including Alzheimer’s, Frontotemporal Dementia and Parkinson’s. These disorders impact memory, movement, language, behavior and personality resulting in disability and death of millions of patients around the globe. 

We focus our groundbreaking science on identifying new medicines to preserve cognition and other brain functions and enhance resilience to neurodegenerative diseases.  Our name reflects this focus:  Muna means ‘to remember’ in Old Norse. 

Michael J. Fox Foundation

Sanofi Ventures

Novo Holdings

Polaris Partners

Droia Ventures

Sofinnova Partners

LS Polaris Innovation Fund

LSP BioVentures

V-Bio Ventures

We are recruiting for two Research Associates to join #Muna_Therapeutics' MiND-MAP team in #Leuven, #Belgium.  MiND-MAP is our innovative, all-in-human drug target discovery and validation platform.  MiND-MAP utilizes spatial transcriptomics from postmortem brain samples to understand cellular and molecular responses to misfolded protein and other pathologies and advance these insights into novel drug targets. The role description and how to apply are in the document below. #muna_tx #neurodegeneration #neuroinflammation #Alzheimers #biotech

I am presenting new insights into Kv1.3 blockers as therapeutics for #Parkinson’s and progressive #MS (poster #445) and the impact of MiND-MAP (#151), Muna Therapeutics  all-in-human #alzheimers target mining and validation platform, at #ADPD2024. Also visit our poster on TREM2 agonists (#147)

CEOs of some of the hottest and most innovative companies in CNS Neuroscience drug development are speaking at Bio-Neuroscience. Join them at the summit for leading CEOs, investors and industry. #BioNeuroscience bio-neuroscience.com Niels Plath Muna Therapeutics Broadreach Global Amsterdam UMC Amsterdam UMC - Amsterdam Neuroscience Andrea Soto Padilla Pieter van Bokhoven Paweł Świeboda Naomi Glover, MSc, FRSA, FRSPH European Brain Council

Niels Plath, Muna Tx’s CSO, will be speaking about our work on next generation therapeutics for neurodegenerative diseases at Bio-Neuroscience in Amsterdam.

As we advance our work to the clinic to bring patients therapeutic options for #neurodegenerativediseases, we at Muna Therapeutics have serious fun, every day - check out the video clip below! #muna_tx #neuroscience #neurodegeneration  #alzheimersdisease #parkinsonsdisease #multiplesclerosis #biotech #neurology

Metric
Company Name	Muna Therapeutics	Therini Bio
Symbol
MSH ID	COM:MUNATHERAPEUTICS	COM:THERINIBIO
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	DK	US
Stage
Employee Count	52
Website	munatherapeutics.com	therinibio.com
LinkedIn	muna-therapeutics	therinibio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

MUNA

COM:MUNATHERAPEUTICS

Muna Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue